Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 13 | 2022 | 66 | 2.690 |
Why?
|
| Analgesics, Opioid | 9 | 2022 | 117 | 2.260 |
Why?
|
| Ceftazidime | 3 | 2022 | 15 | 2.120 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2022 | 60 | 1.770 |
Why?
|
| Fentanyl | 6 | 2021 | 35 | 1.590 |
Why?
|
| Anti-Bacterial Agents | 8 | 2022 | 534 | 1.480 |
Why?
|
| Methadone | 4 | 2019 | 17 | 1.430 |
Why?
|
| Infant, Newborn | 14 | 2022 | 899 | 1.380 |
Why?
|
| Child | 27 | 2022 | 2271 | 1.260 |
Why?
|
| Neonatal Abstinence Syndrome | 3 | 2019 | 10 | 1.070 |
Why?
|
| Anti-Infective Agents | 4 | 2017 | 78 | 1.070 |
Why?
|
| Retrospective Studies | 18 | 2023 | 2612 | 1.060 |
Why?
|
| Infant | 14 | 2022 | 1019 | 1.040 |
Why?
|
| Hypnotics and Sedatives | 6 | 2022 | 29 | 1.000 |
Why?
|
| Humans | 51 | 2023 | 28581 | 0.990 |
Why?
|
| Hyponatremia | 3 | 2021 | 17 | 0.960 |
Why?
|
| Gram-Negative Bacteria | 3 | 2022 | 62 | 0.940 |
Why?
|
| Ketamine | 2 | 2022 | 10 | 0.860 |
Why?
|
| Child, Preschool | 14 | 2021 | 1167 | 0.810 |
Why?
|
| Medication Therapy Management | 2 | 2019 | 20 | 0.760 |
Why?
|
| Cephalosporins | 1 | 2022 | 18 | 0.750 |
Why?
|
| Education, Pharmacy | 2 | 2021 | 117 | 0.730 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2019 | 611 | 0.730 |
Why?
|
| Meningitis | 1 | 2020 | 12 | 0.680 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 62 | 0.670 |
Why?
|
| Tobramycin | 2 | 2017 | 13 | 0.670 |
Why?
|
| Metronidazole | 2 | 2017 | 16 | 0.660 |
Why?
|
| Streptococcal Infections | 1 | 2020 | 37 | 0.660 |
Why?
|
| Pharmacy Residencies | 1 | 2020 | 6 | 0.650 |
Why?
|
| Bacteremia | 1 | 2020 | 81 | 0.640 |
Why?
|
| Obesity | 5 | 2023 | 675 | 0.640 |
Why?
|
| Pharmacists | 2 | 2022 | 74 | 0.630 |
Why?
|
| Students, Pharmacy | 2 | 2020 | 84 | 0.630 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 14 | 0.630 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2016 | 41 | 0.610 |
Why?
|
| Disease Management | 2 | 2017 | 90 | 0.600 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 44 | 0.600 |
Why?
|
| Opioid-Related Disorders | 4 | 2013 | 42 | 0.600 |
Why?
|
| Analgesics | 5 | 2016 | 38 | 0.600 |
Why?
|
| Infant, Premature | 2 | 2017 | 144 | 0.580 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2017 | 3 | 0.550 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2017 | 3 | 0.550 |
Why?
|
| Amiodarone | 1 | 2017 | 11 | 0.550 |
Why?
|
| Anesthetics, Intravenous | 1 | 2017 | 15 | 0.530 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2017 | 117 | 0.530 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2022 | 148 | 0.510 |
Why?
|
| Male | 19 | 2020 | 13771 | 0.490 |
Why?
|
| Aminoglycosides | 1 | 2014 | 10 | 0.450 |
Why?
|
| Pediatrics | 3 | 2022 | 92 | 0.450 |
Why?
|
| Hyperphosphatemia | 1 | 2014 | 4 | 0.450 |
Why?
|
| Amphotericin B | 1 | 2014 | 19 | 0.440 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 4 | 0.440 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 224 | 0.440 |
Why?
|
| Female | 19 | 2020 | 15471 | 0.440 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2019 | 10 | 0.440 |
Why?
|
| Body Fluids | 1 | 2014 | 18 | 0.440 |
Why?
|
| Narcotic Antagonists | 2 | 2011 | 32 | 0.430 |
Why?
|
| Language Development | 1 | 2013 | 5 | 0.420 |
Why?
|
| Antifungal Agents | 1 | 2014 | 67 | 0.420 |
Why?
|
| Alkalosis | 1 | 2013 | 2 | 0.420 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2013 | 6 | 0.420 |
Why?
|
| Acetazolamide | 1 | 2013 | 9 | 0.420 |
Why?
|
| Motor Skills | 1 | 2013 | 34 | 0.410 |
Why?
|
| Bumetanide | 1 | 2012 | 2 | 0.390 |
Why?
|
| Overweight | 2 | 2011 | 113 | 0.380 |
Why?
|
| Education, Pharmacy, Graduate | 3 | 2022 | 18 | 0.380 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 14 | 0.370 |
Why?
|
| Pharmaceutical Services | 2 | 2022 | 41 | 0.360 |
Why?
|
| Infusions, Intravenous | 5 | 2017 | 102 | 0.360 |
Why?
|
| Pharmacy | 2 | 2022 | 35 | 0.360 |
Why?
|
| Pruritus | 1 | 2011 | 8 | 0.360 |
Why?
|
| Hydromorphone | 2 | 2021 | 8 | 0.350 |
Why?
|
| Cognition | 1 | 2013 | 327 | 0.330 |
Why?
|
| Cohort Studies | 4 | 2022 | 893 | 0.330 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 74 | 0.330 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2009 | 9 | 0.320 |
Why?
|
| Medication Errors | 1 | 2009 | 26 | 0.310 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 27 | 0.310 |
Why?
|
| Adolescent | 7 | 2021 | 3165 | 0.300 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 113 | 0.290 |
Why?
|
| Otitis Media | 1 | 2007 | 35 | 0.270 |
Why?
|
| Clonidine | 3 | 2016 | 10 | 0.230 |
Why?
|
| Age Factors | 2 | 2019 | 734 | 0.230 |
Why?
|
| Vancomycin | 2 | 2017 | 58 | 0.220 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 42 | 0.220 |
Why?
|
| Acyclovir | 1 | 2023 | 8 | 0.200 |
Why?
|
| Writing | 2 | 2020 | 14 | 0.200 |
Why?
|
| Educational Measurement | 2 | 2021 | 131 | 0.200 |
Why?
|
| Cefotaxime | 1 | 2022 | 5 | 0.190 |
Why?
|
| Monobactams | 1 | 2022 | 6 | 0.190 |
Why?
|
| Curriculum | 3 | 2019 | 296 | 0.190 |
Why?
|
| Bias | 1 | 2022 | 42 | 0.180 |
Why?
|
| Critical Care | 2 | 2012 | 49 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 244 | 0.180 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 30 | 0.180 |
Why?
|
| Chlorothiazide | 1 | 2021 | 3 | 0.170 |
Why?
|
| Fatty Acids, Essential | 1 | 2020 | 3 | 0.170 |
Why?
|
| Sodium | 1 | 2021 | 50 | 0.170 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 3 | 2016 | 10 | 0.170 |
Why?
|
| Ampicillin | 1 | 2020 | 14 | 0.170 |
Why?
|
| Streptococcus agalactiae | 1 | 2020 | 12 | 0.170 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2020 | 16 | 0.170 |
Why?
|
| Narration | 1 | 2020 | 20 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 76 | 0.160 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 107 | 0.160 |
Why?
|
| Research | 1 | 2020 | 93 | 0.160 |
Why?
|
| Prognosis | 1 | 2022 | 807 | 0.150 |
Why?
|
| Employment | 1 | 2019 | 49 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2022 | 250 | 0.150 |
Why?
|
| Escherichia coli | 1 | 2022 | 338 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 22 | 0.150 |
Why?
|
| Career Choice | 1 | 2019 | 53 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 67 | 0.150 |
Why?
|
| Coronary Disease | 1 | 2019 | 120 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 988 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 64 | 0.140 |
Why?
|
| Injections, Intradermal | 1 | 2017 | 2 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 36 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2017 | 36 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 34 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2017 | 67 | 0.130 |
Why?
|
| Adult | 7 | 2023 | 7922 | 0.130 |
Why?
|
| Patient Admission | 1 | 2016 | 29 | 0.120 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 5 | 0.120 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 8 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 34 | 0.120 |
Why?
|
| Shock | 1 | 2016 | 17 | 0.120 |
Why?
|
| Norwood Procedures | 1 | 2016 | 13 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2016 | 68 | 0.120 |
Why?
|
| United States | 2 | 2019 | 2201 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2016 | 68 | 0.110 |
Why?
|
| Amikacin | 1 | 2014 | 4 | 0.110 |
Why?
|
| Gentamicins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 44 | 0.110 |
Why?
|
| Pregnancy | 1 | 2019 | 1219 | 0.110 |
Why?
|
| Phosphorus | 1 | 2014 | 53 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 173 | 0.110 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2013 | 23 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2013 | 210 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 216 | 0.100 |
Why?
|
| Hemodynamics | 1 | 2014 | 221 | 0.100 |
Why?
|
| Time Factors | 1 | 2017 | 1600 | 0.100 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2009 | 9 | 0.100 |
Why?
|
| Conscious Sedation | 1 | 2012 | 10 | 0.100 |
Why?
|
| Analgesia | 1 | 2012 | 13 | 0.100 |
Why?
|
| Nursing Assessment | 1 | 2012 | 27 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 426 | 0.090 |
Why?
|
| Middle Aged | 3 | 2019 | 7310 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2012 | 28 | 0.090 |
Why?
|
| Pain Management | 1 | 2012 | 62 | 0.090 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2011 | 18 | 0.090 |
Why?
|
| Naloxone | 1 | 2011 | 19 | 0.090 |
Why?
|
| Naltrexone | 1 | 2011 | 19 | 0.090 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2011 | 7 | 0.090 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2021 | 22 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2016 | 631 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2012 | 108 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2012 | 458 | 0.080 |
Why?
|
| Risk Factors | 1 | 2014 | 2111 | 0.070 |
Why?
|
| Hospitalization | 1 | 2009 | 199 | 0.070 |
Why?
|
| Quality of Life | 1 | 2011 | 504 | 0.070 |
Why?
|
| Drug Tolerance | 2 | 2021 | 37 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2007 | 273 | 0.060 |
Why?
|
| Oklahoma | 2 | 2020 | 1038 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 40 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 250 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2021 | 50 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 97 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2019 | 18 | 0.040 |
Why?
|
| Furosemide | 1 | 2019 | 7 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2019 | 79 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 46 | 0.040 |
Why?
|
| Occupations | 1 | 2018 | 9 | 0.040 |
Why?
|
| Feedback | 1 | 2018 | 33 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2019 | 231 | 0.040 |
Why?
|
| Education | 1 | 2018 | 33 | 0.040 |
Why?
|
| Aged | 2 | 2019 | 5525 | 0.040 |
Why?
|
| Scholarly Communication | 1 | 2018 | 4 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 259 | 0.040 |
Why?
|
| Accreditation | 1 | 2018 | 36 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 93 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 25 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 405 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 85 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 56 | 0.030 |
Why?
|
| Learning | 1 | 2018 | 99 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 60 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 393 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 325 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 352 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 622 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 183 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 15 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 16 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 75 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1026 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 994 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2045 | 0.030 |
Why?
|
| Opiate Substitution Treatment | 1 | 2013 | 8 | 0.030 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 7 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 172 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 31 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 2402 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 77 | 0.020 |
Why?
|
| Anxiety | 1 | 2012 | 157 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 782 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 302 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2804 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 409 | 0.020 |
Why?
|
| Dexmedetomidine | 1 | 2009 | 2 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 10580 | 0.010 |
Why?
|